Hospital Da Luz S.A.

Hospital Da Luz S.A. is conducting studies that aim to reduce heart‑related events and improve outcomes for patients with various cardiac conditions. Trials evaluate new lipid‑lowering agents, anti‑inflammatory therapies, and novel anticoagulants to prevent heart failure progression, stroke, and atrial fibrillation complications.

• Heart failure with preserved ejection fraction and systemic inflammation
• Primary prevention of atherosclerotic cardiovascular disease
• Ischemic stroke prevention after acute non‑cardioembolic stroke or high‑risk TIA
• Reducing stroke and systemic embolism risk in atrial fibrillation
• Long‑term impact of inclisiran on major adverse cardiovascular events

These investigations reflect the site’s commitment to advancing cardiovascular care through innovative therapies.

Research at the internal medicine department focuses on inflammatory bowel conditions, seeking treatments that achieve endoscopic healing and sustained symptom relief.

• Efficacy of a novel oral agent for moderately to severely active ulcerative colitis
• Assessment of endoscopic improvement and remission rates
• Safety profile of emerging therapies in chronic colitis

The trials aim to provide patients with more effective options for managing digestive inflammation.

The site is engaged in oncology studies targeting both solid tumors and hematologic malignancies, with the goal of extending survival and improving quality of life for cancer patients.

• Advanced ER‑positive, HER2‑negative breast cancer treatment comparisons
• Therapy for unresectable or metastatic melanoma using novel immune agents
• Evaluation of small cell lung cancer regimens versus standard chemotherapy
• Combination chemoradiotherapy for esophageal carcinoma
• Strategies for breast neoplasms with high recurrence risk

These cancer trials reflect a multidisciplinary effort to test new biologics and targeted medicines.

Clinical investigations address both episodic and chronic neurological disorders, exploring preventive and disease‑modifying approaches.

• Preventive therapy for chronic and episodic migraine comparing novel agents to established treatments
• Long‑term safety of tolebrutinib in relapsing and progressive multiple sclerosis
• Evaluation of central nervous system disease outcomes in broader neuro‑health trials

The research aims to reduce migraine frequency and slow multiple sclerosis progression.

Studies in this therapeutic area target weight management and metabolic health, especially in younger populations, to curb the growing burden of obesity.

• Pediatric weight‑loss efficacy of semaglutide in children aged 6–12 years
• Impact of lifestyle‑adjunct therapy on obesity and overweight in adults
• Cardiovascular safety assessment of a novel agent in participants with excess body weight

These trials seek to provide sustainable solutions for metabolic disease prevention.